<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3386">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571389</url>
  </required_header>
  <id_info>
    <org_study_id>BioCytics 0001</org_study_id>
    <secondary_id>WIRB Protocol # 20070969</secondary_id>
    <nct_id>NCT00571389</nct_id>
  </id_info>
  <brief_title>Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products</brief_title>
  <official_title>A Study to Facilitate Development of an Ex-Vivo Device Platform for Circulating Tumor Cell and Immune Cell Harvesting, Banking, and Apoptosis-Viability Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCytics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCytics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      This is a study to investigate the feasibility of harvesting, expanding in culture, and
      freezing circulating tumor cells and immune cells from cancer patients and healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Healthy Donors</condition>
  <condition>COVID-19 Donors</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral whole blood, immune cells, circulating tumor cells, discarded tissue obtained from
      biopsies and fluid (paracentesis, pleuracentesis), plasma-leukapheresis products, saliva,
      urine and stool.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population of patients to be enrolled for this study will be adults (males and females)
        with histological proven solid tumors of any stage, seen for routine cancer care at
        participating community cancer clinic sites. Patients on clinical trials with experimental
        study drugs will be allowed to participate in this observational prospective study.

        Healthy volunteers will also make up a portion of the study population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Biospecimen(s) collection:

          -  Histological diagnosis of metastatic stage IV or locally advanced (unresectable) stage
             III cancer of any solid tumor type, histological non-metastatic cancer of any solid
             tumor type of any stage and healthy volunteers

          -  Age ≥ 18yo

          -  Life expectancy ≥ 12 weeks

          -  ECOG Performance Status of 0, 1, 2, or 3 (Appendix 2)

          -  Negative serology screening test for HIV, HBV and HCV; in event of a postive result, a
             reflex PCR may be performed and if negative, the pt may be allowed on the study

        Additional Subject Eligibility for Leukapheresis Collection:

          -  ECOG Performance Status of 0 or 1

          -  Screening laboratory values must meet following criteria on leukapheresis collection
             day:

               -  WBC ≥ 2000/µL

               -  Neutrophils ≥ 1500/µL

               -  Platelets ≥ 100 x103/µL

               -  Hemoglobin ≥ 9 g/dL

               -  Creatinine ≤ 2.5 x ULN

               -  AST ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases

               -  Bilirubin ≤ 2 x ULN (except patients with Gilbert's syndrome, who must have total
                  bilirubin &lt; 3.0 mg/dL)

        Exclusion Criteria:

          -  Patients with any active infection requiring therapy (fever, localizing source) will
             be excluded until the infection resolves.

          -  Confirmed PCR test result for HIV, HBV or HCV

          -  Underlying medical condition that, in the Principal Investigator's or treating
             oncologist's opinion, will obscure the interpretation of the patient's safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Powderly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolina BioOncology Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Powderly, MD</last_name>
    <phone>704-947-6599</phone>
    <email>jpowderly@carolinabiooncology.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle Emery, MD, CCRC</last_name>
      <phone>704-947-6599</phone>
      <phone_ext>1147</phone_ext>
      <email>remery@carolinabiooncology.org</email>
    </contact>
    <investigator>
      <last_name>Rochelle Emery, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.carolinabiooncology.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>All Stages of cancer</keyword>
  <keyword>All stages of solid tumor origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

